Business Wire

Specifica Validates Best-in-Class Status for in vitro Antibody Discovery Platform in Two Key Peer Reviewed Publications

Share

Specifica, a privately held antibody engineering company focused on innovative in vitro antibody library and discovery tools, announced the publication of two peer-reviewed articles describing its Generation 3 Antibody Discovery Platform1,2.

Antibodies are the fastest growing class of therapeutics, representing nine of the top twenty best-selling drugs3. The global antibody therapy market is projected to grow from $178.50 billion in 2021 to $451.89 billion in 2028 at a CAGR of 14.1%4. Traditionally, therapeutic antibodies have been generated by harvesting immune responses, either from in-bred or transgenic mice, or from immune human subjects. Although there has been a long-standing interest in using in vitro antibody library approaches that avoid the use of animals, there have been two main concerns with antibodies from in vitro libraries: binding affinities tend to be lower, and poor developability characteristics are common, complicating their development as successful drugs. As described in these articles, Specifica has overcome both of these concerns.

In the Mabs article1, Specifica explains the scientific rationale behind the new Gen 3 platform. Specifica’s Gen 3 antibody libraries combine the use of well-behaved antibodies already validated in the clinic as frameworks, with scaffold-compatible binding loop sequences (CDRs) from natural antibodies, devoid of most sequence liabilities to improve developability. In selection campaigns with the Gen 3 platform, both phage and yeast display are employed. The results described in this article demonstrate the power of the platform to directly generate a broad diversity of specific antibodies (100-1000 different clusters) with high affinity (20% subnanomolar) and few developability issues.

The Nature Communications article2, published this week, compares antibodies generated against SARS-CoV-2 using the Gen 3 platform with hundreds of other antibodies described in the literature, from over 50 different laboratories. Specifica’s Gen 3 antibodies out-performed all other antibodies sourced from naïve libraries, showed better performance than the majority of immune-sourced antibodies, and were comparable to the very best immune SARS-CoV-2 antibodies in terms of affinity and viral neutralization, with developability properties as good as the best already approved antibodies.

“These two papers validate the Gen 3 platform’s best-in-class status, fulfilling the original promise of naive antibody libraries made over 30 years ago, namely, to eliminate the use of animals or immune sources to generate powerful antibodies,” said Andrew Bradbury, co-founder and CSO of Specifica.

About Specifica

Specifica is a rapidly growing antibody engineering company providing best-in-class in vitro antibody discovery libraries, selection and informatics tools, and discovery and optimization services to the pharmaceutical industry. Specifica’s patented5 Generation 3 Antibody Library Discovery Platform yields drug-like antibodies, with broad diversity, high affinities, and few biophysical liabilities directly from selections, minimizing the need for downstream affinity and biophysical engineering. In addition to in-house antibody library designs, Specifica also collaborates closely with partners to create custom libraries in which essential elements are optimized according to partner needs. The power of the Gen 3 platform may be accessed by engaging Specifica to execute antibody discovery campaigns, or by full transfer of the platform technology in-house. In 2021, Specifica executed agreements with 10 new companies, and initiated 16 new discovery and optimization programs, expanding on 5 of its existing partnerships. Additionally, in cooperation with its software partner OpenEye, Specifica lauched AbXtract, a new suite of antibody informatics tools. Specifica is headquartered in Santa Fe, New Mexico. For more information, please visit www.specifica.bio and follow Specifica on Twitter and LinkedIn.

1 https://www.tandfonline.com/doi/full/10.1080/19420862.2021.1980942 (2021)
2 https://www.nature.com/articles/s41467-021-27799-z (2022).
3 https://www.nature.com/articles/d41573-021-00079-7 (2021).
4 https://www.fortunebusinessinsights.com/monoclonal-antibody-therapy-market-102734 (2021).
5 US patent 10,954,508 (2020).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Andrew Bradbury, CSO
Specifica, Inc.
505-216-2445

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Conviva Announces Streaming Audience Measurement Standard Leveraging Comprehensive, Continuous, Census-level Technology16.5.2022 21:21:00 EEST | Press release

Conviva, the Continuous Measurement Analytics platform for streaming media, today announces it will unveil a streaming audience measurement standard to be released for general availability at CES 2023. This expansion is in partnership with premium streaming providers using Conviva’s real-time cloud sessionization technology. The new standard provides census-level streaming audience ad packaging and measurement that is complimentary and interoperable with linear TV allowing streaming providers to compete at scale with the digital walled gardens solutions competing for ad budgets today. Conviva’s platform currently processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. “Audience measurement represents the streaming industry’s biggest opportunity and Conviva’s technology definitively unlocks its potential,” comments Keith Zubchevich, CEO of Conviva. “

Verimatrix Anti-Piracy and Threat Defense Experts To Highlight Latest Innovations at CABSAT and TT CS16.5.2022 18:45:00 EEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced participation in two leading conferences this month: European Medical Device and Diagnostic Software Development and Compliance Conference (TT CS) – May 17-18 – Brussels, Belgium TT CS is Europe’s only dedicated conference for medtech cybersecurity professionals. Held at the Sheraton Brussels Airport Hotel, the event features two Verimatrix speakers. Nicole Lua, sales director, is scheduled to serve as moderator for a “Security By Design” roundtable at 1:35 p.m. on May 17. Neal Michie, director of product management, is scheduled to discuss the prevention of threats associated with unmanaged and quasi-managed devices during a session slated for 10:15-10:50 a.m. on May 18. CABSAT – May 17-19 – Dubai, UAE CABSAT is the most established and respected trade platform for broadcast, satellite, entertainment content & digital media sectors across

“Our Future is Light” Campaign Kicks off 2022 International Day of Light16.5.2022 18:03:00 EEST | Press release

An action-packed video styled as a blockbuster-movie trailer provides the linchpin for this year’s International Day of Light (IDL) campaign, “Our future is light. Play your part.” Released today, Day of Light features diverse characters successfully solving global-level problems using photonics-enabled technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005150/en/ Sponsored by SPIE, Optica, and IEEE Photonics Society, this year’s International Day of Light celebration showcases exciting, critical career opportunities in optics and photonics. (Graphic: Business Wire) Three professional societies – SPIE, the international society for optics and photonics, IEEE Photonics Society, and Optica, Advancing Optics & Photonics Worldwide – partnered to create the video and the accompanying 2022 IDL campaign. “Our future is light. Play your part” promotes the importance of light-based technologies and interesting careers

NielsenIQ Launches Retail Media Solution to Monetize Assets and Measure ROI for Retailers16.5.2022 17:01:00 EEST | Press release

Today, NielsenIQ, a global information services company, announced the launch of NielsenIQ Activate; a software-as-a-service (SaaS) solution that enables retailers to accelerate revenue opportunities through retail media and comprehensive customer insights that activate shoppers with personalized promotional offers. NielsenIQ Activate is comprised of dedicated applications for hyper-targeted audience building, offer and ads management, and end-to-end measurement. This SaaS tool, part of the NielsenIQ Connect platform, will allow retailers to create sustainable revenues by monetizing their retail media assets across physical and digital channels. Additionally, retailers will be able to boost credibility with brands and inform them of the insights they need to command their customers’ attention, act on those insights, and measure the ROI of their activities across all channels. “We are devoted to continuing our legacy by defining the next century of consumer and retail measurement,” says

TYLin and GPO Group Strategically Align16.5.2022 17:00:00 EEST | Press release

The GPO Group and Sam Schwartz, one of its operating companies, as part of a global effort to enhance connections and collaboration among companies in the Dar Group’s Global Infrastructure (GI) Pillar, are formally aligning with TYLin, the leading brand in the GI Pillar. The GPO Group and Sam Schwartz have added a TYLin “unifier” line to their names. Effective immediately, GPO will be known as GPO, A TYLin Company. Similarly, Sam Schwartz will be known as Sam Schwartz, A TYLin Company. The addition of the unifier line is part of a global strategic initiative to unify the companies in the Dar Group GI Pillar under the TYLin brand to provide more efficient access to its vast global resources and promote better collaboration among its staff. Aligning the two companies with TYLin — particularly in the rail and transit segments — means that GPO and Sam Schwartz, transportation and mobility leaders in Europe and the Americas, respectively, will expand their ability to deliver innovative thin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom